STOCK-BASED COMPENSATION	6 Months Ended
Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	STOCK-BASED COMPENSATION BioScrip Equity Incentive Plans Under the Company’s Amended and Restated 2008 Equity Incentive Plan (the “2008 Plan”), the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights (“SARs”), restricted stock grants, restricted stock units, performance shares and performance units to key employees and directors. While SARs are authorized under the 2008 Plan, they may also be issued outside of the plan. The 2008 Plan is administered by the Company’s Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors. On November 30, 2016, at a special meeting, the stockholders approved (i) an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the number of shares of Common Stock that the Company is authorized to issue from 125 million shares to 250 million shares (the “Charter Amendment”); (ii) an amendment to the 2008 Plan to (a) increase the number of shares of Common Stock in the aggregate that may be subject to awards by 5,250,000 shares, from 9,355,000 to 14,605,000 shares and (b) increase the annual grant caps under the Company’s 2008 Plan from 500,000 Options, 500,000 Stock Appreciation Rights and 350,000 Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code to a cap of no more than a total of 3,000,000 Options, Stock Appreciation Rights, Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code combined; and (iii) if necessary, an adjournment of the Stockholders’ Meeting if there were insufficient votes in favor of the Charter Amendment. As of June 30, 2017, 4,360,887 shares remain available for grant under the 2008 Plan. Stock Options The Company recognized compensation expense related to stock options of $0.3 million and $0.7 million during the three months ended June 30, 2017 and 2016, respectively, and $0.6 million and $1.7 million during the six months ended June 30, 2017 and 2016, respectively. Restricted Stock The Company recognized $0.1 million and a nominal amount of compensation expense related to restricted stock awards during the three months ended June 30, 2017 and 2016, respectively, and $0.3 million and a nominal amount of compensation expense during the six months ended June 30, 2017 and 2016, respectively. Stock Appreciation Rights and Market Based Cash Awards The Company recognized nominal amounts of compensation expense related to stock appreciation rights awards during the three months ended June 30, 2017 and 2016, and nominal and $0.1 million of compensation expense during the six months ended June 30, 2017 and 2016, respectively. The Company recognized nominal compensation expense and $0.2 million compensation benefit related to market based cash awards during the three months ended June 30, 2017 and 2016, respectively, and nominal and $0.1 million compensation expense during six months ended June 30, 2017 and 2016, respectively. Employee Stock Purchase Plan On May 7, 2013, the Company’s stockholders approved the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP is administered by the Compensation Committee. The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the quarterly offering period. The Company filed a Registration Statement on Form S-8 to register 750,000 shares of Common Stock, par value $0.0001 per share, for issuance under the ESPP. As of June 30, 2017, 136,713 shares remained available for grant under the ESPP. Since inception, the ESPP’s third-party service provider has purchased 613,287 shares on the open market and delivered these shares to the Company’s employees pursuant to the ESPP. During the three months ended June 30, 2017 and 2016, and the six months ended June 30, 2017 and 2016, the Company incurred less than $0.1 million of expense related to the ESPP.

STOCK-BASED COMPENSATION

BioScrip Equity Incentive Plans

Under the Company’s Amended and Restated 2008 Equity Incentive Plan (the “2008 Plan”), the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights (“SARs”), restricted stock grants, restricted stock units, performance shares and performance units to key employees and directors. While SARs are authorized under the 2008 Plan, they may also be issued outside of the plan. The 2008 Plan is administered by the Company’s Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors.

On November 30, 2016, at a special meeting, the stockholders approved (i) an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the number of shares of Common Stock that the Company is authorized to issue from 125 million shares to 250 million shares (the “Charter Amendment”); (ii) an amendment to the 2008 Plan to (a) increase the number of shares of Common Stock in the aggregate that may be subject to awards by 5,250,000 shares, from 9,355,000 to 14,605,000 shares and (b) increase the annual grant caps under the Company’s 2008 Plan from 500,000 Options, 500,000 Stock Appreciation Rights and 350,000 Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code to a cap of no more than a total of 3,000,000 Options, Stock Appreciation Rights, Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code combined; and (iii) if necessary, an adjournment of the Stockholders’ Meeting if there were insufficient votes in favor of the Charter Amendment.

As of June 30, 2017, 4,360,887 shares remain available for grant under the 2008 Plan.

Stock Options

The Company recognized compensation expense related to stock options of $0.3 million and $0.7 million during the three months ended June 30, 2017 and 2016, respectively, and $0.6 million and $1.7 million during the six months ended June 30, 2017 and 2016, respectively.

Restricted Stock

The Company recognized $0.1 million and a nominal amount of compensation expense related to restricted stock awards during the three months ended June 30, 2017 and 2016, respectively, and $0.3 million and a nominal amount of compensation expense during the six months ended June 30, 2017 and 2016, respectively.

Stock Appreciation Rights and Market Based Cash Awards

The Company recognized nominal amounts of compensation expense related to stock appreciation rights awards during the three months ended June 30, 2017 and 2016, and nominal and $0.1 million of compensation expense during the six months ended June 30, 2017 and 2016, respectively.

The Company recognized nominal compensation expense and $0.2 million compensation benefit related to market based cash awards during the three months ended June 30, 2017 and 2016, respectively, and nominal and $0.1 million compensation expense during six months ended June 30, 2017 and 2016, respectively.

Employee Stock Purchase Plan

On May 7, 2013, the Company’s stockholders approved the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP is administered by the Compensation Committee. The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the quarterly offering period. The Company filed a Registration Statement on Form S-8 to register 750,000 shares of Common Stock, par value $0.0001 per share, for issuance under the ESPP.

As of June 30, 2017, 136,713 shares remained available for grant under the ESPP. Since inception, the ESPP’s third-party service provider has purchased 613,287 shares on the open market and delivered these shares to the Company’s employees pursuant to the ESPP. During the three months ended June 30, 2017 and 2016, and the six months ended June 30, 2017 and 2016, the Company incurred less than $0.1 million of expense related to the ESPP.